These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35003324)

  • 1. Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient's Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
    Liu H; Lv L; Gao H; Cheng M
    Comput Math Methods Med; 2021; 2021():7545091. PubMed ID: 35003324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
    Spring LM; Fell G; Arfe A; Sharma C; Greenup R; Reynolds KL; Smith BL; Alexander B; Moy B; Isakoff SJ; Parmigiani G; Trippa L; Bardia A
    Clin Cancer Res; 2020 Jun; 26(12):2838-2848. PubMed ID: 32046998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
    Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
    Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
    Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
    Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
    Broglio KR; Quintana M; Foster M; Olinger M; McGlothlin A; Berry SM; Boileau JF; Brezden-Masley C; Chia S; Dent S; Gelmon K; Paterson A; Rayson D; Berry DA
    JAMA Oncol; 2016 Jun; 2(6):751-60. PubMed ID: 26914222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
    Peterson JR; Cole JA; Pfeiffer JR; Norris GH; Zhang Y; Lopez-Ramos D; Pandey T; Biancalana M; Esslinger HR; Antony AK; Takiar V
    Breast Cancer Res; 2023 May; 25(1):54. PubMed ID: 37165441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
    Liu S; Duan X; Xu L; Ye J; Cheng Y; Liu Q; Zhang H; Zhang S; Zhu S; Li T; Liu Y
    Tumour Biol; 2016 Apr; 37(4):4873-81. PubMed ID: 26526577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies.
    Wan T; Zhang XF; Liang C; Liao CW; Li JY; Zhou YM
    Ann Surg Oncol; 2019 May; 26(5):1412-1420. PubMed ID: 30805807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy.
    Chaudry M; Lei X; Gonzalez-Angulo AM; Mittendorf EA; Valero V; Tripathy D; Hortobagyi GN; Chavez-MacGregor M
    Breast Cancer Res Treat; 2015 Sep; 153(2):417-23. PubMed ID: 26272743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
    Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
    Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
    Kim MM; Allen P; Gonzalez-Angulo AM; Woodward WA; Meric-Bernstam F; Buzdar AU; Hunt KK; Kuerer HM; Litton JK; Hortobagyi GN; Buchholz TA; Mittendorf EA
    Ann Oncol; 2013 Aug; 24(8):1999-2004. PubMed ID: 23562929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
    Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
    Front Oncol; 2021; 11():736769. PubMed ID: 34868925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.
    Gogate A; Ranjan S; Kumar A; Bhandari H; Papademetriou E; Kim I; Potluri R
    Front Oncol; 2023; 13():1119102. PubMed ID: 37205193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
    Huang M; Fasching PA; Haiderali A; Xue W; Pan W; Karantza V; Yang F; Truscott J; Xin Y; O'Shaughnessy J
    Future Oncol; 2024 Feb; 20(6):335-348. PubMed ID: 37602372
    [No Abstract]   [Full Text] [Related]  

  • 20. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.